SynthesisBMC infectious diseases2025
Global trends in macrolide and lincosamide resistance in Streptococcus species: a comprehensive systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical and Epidemiological Landscape of Antimicrobial Resistance and Virulence inAntibiotics (Basel, Switzerland) · 2026Review
- Species Identification and Antimicrobial Resistance ofAnimals : an open access journal from MDPI · 2026Article
- Evaluating the use of whole-genome sequencing and SangerJournal of medical microbiology · 2026Article
- Development of Membrane-Targeting Cannabigerol Derivatives as Potent Broad-Spectrum Antibacterial Agents.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe widespread use of macrolides and lincosamides, particularly for treating infections caused by Streptococcus pyogenes (S. pyogenes) (group A Streptococcus (GAS)), and S. pneumoniae has led to a concerning rise in antibiotic resistance. This meta-analysis aimed to evaluate the weighted pooled resistance rates of macrolides and lincosamides in clinical isolates of S. pneumoniae, S. pyogenes, and S. agalactiae (group B Streptococcus (GBS)) based on time, geographical areas, antimicrobial susceptibility testing, and guidelines.
methodWe systematically searched PubMed, Embase, Web of Science, and Scopus for studies published between 2015 and 2023. Study quality was assessed via the Joanna Briggs Institute Checklist. Resistance rates were calculated with a random-effects model, supplemented by meta-regression, subgroup analyses, and identification of outliers. Statistical analyses were performed in R using the metafor package.
resultsThis review analyzed 276 studies across 62 countries. Pooled resistance was highest for clarithromycin (57.6%) and azithromycin (55.8%), followed by erythromycin (41.5%) and clindamycin (29.5%), all with substantial heterogeneity (I2 > 98%, p < 0.001). Resistance differed significantly across various countries and continents (p < 0.001). Resistance patterns varied notably by species, with S. pneumoniae exhibiting the highest resistance to all tested macrolides and lincosamides, followed closely by S. agalactiae. In contrast, S. pyogenes consistently showed the lowest resistance levels across all antibiotics examined. A significant upward trend in resistance was observed over time for erythromycin (p = 0.019) and clindamycin (p = 0.003). According to the meta-regression, the erythromycin resistance rate increased over time (r = 0.094, p = 0.005).
conclusionMacrolide and lincosamide resistance among key Streptococcus species are alarmingly high and rising globally, with marked species-specific and regional differences. Our findings underscore the urgent need for standardized susceptibility testing protocols, targeted surveillance by species, and enhanced antibiotic stewardship efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.